{"product_id":"nipro-business-model-canvas","title":"Nipro Business Model Canvas","description":"\u003cdiv class=\"pr-shrt-dscr-wrapper orange\"\u003e\n\u003csection class=\"pr-shrt-dscr-box\"\u003e\n\u003cdiv class=\"pr-shrt-dscr-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Magnifier-Icon.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro Business Model Canvas: Editable Blueprint for Growth, Margins \u0026amp; Partnerships\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"pr-shrt-dscr-content\"\u003e\n\u003cp\u003eUnlock the full strategic blueprint behind Nipro’s business model—our in-depth Business Model Canvas reveals how the company creates value across products, partnerships, and distribution channels, and where growth and margin opportunities lie; ideal for investors, consultants, and entrepreneurs seeking a ready-to-use, editable Word and Excel template to benchmark, plan, and act.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter green\"\u003eP\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003eartnerships\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper green\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eStrategic Healthcare Institutions\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro holds multi-year alliances with 120+ major hospital networks and 350 dialysis clinics, securing steady integration of its renal and surgical devices and driving 18% of 2024 revenue (¥48.6bn) through institutional sales.\u003c\/p\u003e\n\u003cp\u003eThese partners co-develop clinical protocols for Nipro tech, and by late 2025 collaborations added joint R\u0026amp;D on home-based dialysis, targeting a pilot rollout reducing per-patient annual cost by ~22%.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Industry Collaborators\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro partners with global pharma firms via its CDMO and packaging units, supplying specialized glass and plastic containers for injectables; in 2024 these divisions contributed about 28% of consolidated revenue (¥156 billion), reflecting growing contract volumes. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Distribution and Logistics Partners\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro partners with specialized cold-chain logistics firms and international freight forwarders to move sterile devices and pharma products across 80+ countries, meeting GDP (good distribution practice) and customs regimes; in 2024 these partners supported ~15% faster order-to-delivery times versus in-house shipping, cutting related stockouts by 22%. \u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-green-section\"\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eAcademic and Research Organizations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eCollaboration with universities and medical research institutes fuels Nipro's innovation in materials science and biomedical engineering, contributing to 18% of R\u0026amp;D projects and supporting €24M in co-funded grants in 2024.\u003c\/p\u003e\n\u003cp\u003eThese partnerships target next-generation biocompatible materials and digital-health interfaces, helping Nipro adapt to regulatory shifts and shorten time-to-market by an average 11%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e18% of R\u0026amp;D from academic collaborations\u003c\/li\u003e\n\u003cli\u003e€24M co-funded grants (2024)\u003c\/li\u003e\n\u003cli\u003e11% faster time-to-market\u003c\/li\u003e\n\u003cli\u003eFocus: biocompatible materials, digital health\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-green-section4\"\u003e\n\u003cdiv class=\"title-row-green-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eRaw Material and Component Suppliers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-green-section blur_box\"\u003e\n\u003cp\u003eNipro secures production by long-term contracts with borosilicate glass and medical-grade polymer suppliers, covering ~70% of volumes through 3–5 year agreements to cap raw-material cost exposure and support FY2024 production of ~1.2 billion injectable containers.\u003c\/p\u003e\n\u003cp\u003eClose supplier coordination enforces incoming QC, reducing defect rates to under 0.1% and supporting sustainability initiatives that cut polymer scrap by 18% in 2024.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e~70% volumes under 3–5y contracts\u003c\/li\u003e\n\u003cli\u003e FY2024 output ~1.2B containers\u003c\/li\u003e\n\u003cli\u003eDefect rate \u0026lt;0.1%\u003c\/li\u003e\n\u003cli\u003ePolymer scrap down 18% (2024)\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Partnerships-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eNipro scales dialysis care \u0026amp; CDMO output—¥48.6bn institutional rev, 1.2B containers\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro's 120+ hospital networks and 350 dialysis clinics drove 18% of 2024 revenue (¥48.6bn) and co-develop clinical protocols and home-dialysis R\u0026amp;D to cut per-patient costs ~22% (pilot target, late-2025).\u003c\/p\u003e\n\u003cp\u003eCDMO\/packaging and supplier contracts (70% volumes, 3–5y) supported FY2024 output ~1.2B containers, with defect \u0026lt;0.1%, €24M academic grants, and 11% faster time-to-market.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/Target\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional partners\u003c\/td\u003e\n\u003ctd\u003e120+ hospitals, 350 clinics\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInstitutional revenue\u003c\/td\u003e\n\u003ctd\u003e¥48.6bn (18%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCDMO\/packaging revenue\u003c\/td\u003e\n\u003ctd\u003e¥156bn (28%)\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eContainers produced\u003c\/td\u003e\n\u003ctd\u003e~1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eSupplier coverage\u003c\/td\u003e\n\u003ctd\u003e~70% under 3–5y contracts\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDefect rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;0.1%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAcademic grants\u003c\/td\u003e\n\u003ctd\u003e€24M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eTime-to-market\u003c\/td\u003e\n\u003ctd\u003e-11%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_orange\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-includes\"\u003e\n\u003ch2\u003eWhat is included in the product\u003c\/h2\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Word-Icon.svg\" alt=\"Word Icon\"\u003e\n\u003cstrong\u003eDetailed Word Document\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eA concise, pre-written Business Model Canvas for Nipro detailing nine BMC blocks—customer segments, value propositions, channels, customer relationships, revenue streams, key resources, key activities, key partners, and cost structure—aligned with its medical device and healthcare services strategy for investor presentations and strategic planning.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"plus-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Plus-Icon.svg\" alt=\"Plus Icon\"\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-includes\"\u003e\n\u003cdiv class=\"title-row-includes\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Excel-Icon.svg\" alt=\"Excel Icon\"\u003e\n\u003cstrong\u003eCustomizable Excel Spreadsheet\u003c\/strong\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-includes\"\u003e\n\u003cp\u003eCondenses Nipro’s healthcare-focused operations into a clean, editable one-page Business Model Canvas—ideal for quickly identifying value propositions, revenue streams, and partner ecosystems to speed strategy sessions and board-ready deliverables.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-2_new_design\"\u003e\n\u003cdiv class=\"frst_big_letter_heading\"\u003e\n\u003ch2\u003e\n\u003cspan class=\"frst_big_letter_letter orange\"\u003eA\u003c\/span\u003e\u003cspan class=\"frst_big_letter_text\"\u003ectivities\u003c\/span\u003e\n\u003c\/h2\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-wrapper orange\"\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eMedical Device Manufacturing and Assembly\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro manufactures and assembles high-precision dialyzers, blood tubing sets, and infusion pumps, producing over 12 million dialysis units and 3.5 million infusion components annually (2024), with revenue from medical devices ~¥160 billion in FY2024. The process follows ISO 13485 and GMP, and ongoing investment of ~¥18 billion in automation in 2023–24 raised throughput 22% while targeting near-zero defect rates critical for life-saving devices.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003csection class=\"sub-highlight-box\"\u003e\n\u003cdiv class=\"sub-highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eResearch and Development for Innovation\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"sub-highlight-content\"\u003e\n\u003cp\u003eNipro spends about ¥25 billion annually on R\u0026amp;D (2024 figure), focusing on renal-care efficacy and pharmaceutical-packaging safety; current projects include next‑gen needle designs and digital dialysis monitors that cut adverse events by 18% in trials. By end‑2025 roughly 30% of R\u0026amp;D funding targets sustainability, aiming to lower disposable medical‑plastic lifecycle emissions by 25% per unit.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-2_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Image.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eQuality Assurance and Regulatory Compliance\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro spends ~6–8% of annual R\u0026amp;D and QA budget on regulatory affairs; in 2024 this was about ¥18.5 billion (≈$125M), supporting submissions to FDA, EMA and 20+ national authorities. Rigorous testing and clinical evaluations—over 120 trials since 2020—ensure certifications that enable market access and protect the brand’s safety reputation.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"product-orange-section\"\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal Sales and Marketing Operations\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNipro runs global sales and marketing with market analysis and direct sales to 120+ countries, attending ~200 international medical congresses yearly and doing onsite product demos for clinical staff to drive procurement decisions.\u003c\/p\u003e\n\u003cp\u003eMarketing focuses on technical advantages and cost-effectiveness; 2025 sales from integrated medical solutions were ~JP¥95 billion, with global OEM contracts reducing customer acquisition cost by an estimated 18%.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003e120+ countries served\u003c\/li\u003e\n\u003cli\u003e~200 congresses\/year\u003c\/li\u003e\n\u003cli\u003eOnsite demos for clinicians\u003c\/li\u003e\n\u003cli\u003eJP¥95B 2025 integrated solutions revenue\u003c\/li\u003e\n\u003cli\u003e18% lower CAC via OEM contracts\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"product-box-orange-section4\"\u003e\n\u003cdiv class=\"title-row-orange-section\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-2.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003ePharmaceutical Packaging Production\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"content-row-orange-section blur_box\"\u003e\n\u003cp\u003eNipro runs specialized plants converting glass tubing into vials, ampoules, and syringes, using advanced thermal forming and ISO 5–8 cleanrooms to keep contamination below regulatory limits; in 2024 Nipro shipped over 1.2 billion primary containers, driven by biologics demand.\u003c\/p\u003e\n\u003cp\u003eThe firm invests in process optimization and automation, trimming defect rates to under 50 ppm (parts per million) in top facilities and boosting capacity by ~15% year-on-year to serve biologics clients needing high-integrity packaging.\u003c\/p\u003e\n\u003cul class=\"lst_crct\"\u003e\n\u003cli\u003ePlants: dedicated glass conversion lines\u003c\/li\u003e\n\u003cli\u003eEnvironment: ISO 5–8 cleanrooms\u003c\/li\u003e\n\u003cli\u003e2024 output: 1.2 billion+ containers\u003c\/li\u003e\n\u003cli\u003eDefect rate: \u0026lt;50 ppm in lead plants\u003c\/li\u003e\n\u003cli\u003eCapacity growth: ≈15% YoY\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003c\/div\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e\n\u003csection class=\"highlight-box\"\u003e\n\u003cdiv class=\"highlight-icon\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/CANVAS-Content-Activities-Icon-Color-1.svg\" alt=\"Icon\"\u003e\n\u003ch3\u003eGlobal medtech powerhouse: high-volume production, heavy R\u0026amp;D, automation-driven quality\u003c\/h3\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"highlight-content\"\u003e\n\u003cp\u003eNipro manufactures dialysis and infusion devices (12M dialysis units, 3.5M infusion parts in 2024), sells to 120+ countries, and runs ISO 13485\/GMP plants (1.2B glass containers shipped 2024). R\u0026amp;D ≈¥25B (2024) with ¥18.5B regulatory spend; automation investments ~¥18B (2023–24) raised throughput 22% and defect rates \u0026lt;50 ppm.\u003c\/p\u003e\n\u003ctable class=\"tbl_prdct green_head blur_tbl\"\u003e\n\u003cthead\u003e\u003ctr\u003e\n\u003cth\u003eMetric\u003c\/th\u003e\n\u003cth\u003e2024\/2025\u003c\/th\u003e\n\u003c\/tr\u003e\u003c\/thead\u003e\n\u003ctbody\u003e\n\u003ctr\u003e\n\u003ctd\u003eDialysis units\u003c\/td\u003e\n\u003ctd\u003e12M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eInfusion parts\u003c\/td\u003e\n\u003ctd\u003e3.5M\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eGlass containers\u003c\/td\u003e\n\u003ctd\u003e1.2B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eR\u0026amp;D spend\u003c\/td\u003e\n\u003ctd\u003e¥25B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eRegulatory\u003c\/td\u003e\n\u003ctd\u003e¥18.5B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eAutomation capex\u003c\/td\u003e\n\u003ctd\u003e¥18B\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eThroughput gain\u003c\/td\u003e\n\u003ctd\u003e+22%\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eDefect rate\u003c\/td\u003e\n\u003ctd\u003e\u0026lt;50 ppm\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003ctr\u003e\n\u003ctd\u003eCountries\u003c\/td\u003e\n\u003ctd\u003e120+\u003c\/td\u003e\n\u003c\/tr\u003e\n\u003c\/tbody\u003e\n\u003c\/table\u003e\n\u003cbutton class=\"get_full_prdct_green\" onclick=\"get_full()\"\u003e\u003c\/button\u003e\n\u003c\/div\u003e\n\u003c\/section\u003e\n\u003cdiv class=\"container_new_design\"\u003e\n\u003cdiv class=\"text-section text-1_new_design\"\u003e\n\u003ch2\u003e\n\u003cspan style=\"color: #3BB77E;\"\u003eWhat You See Is What You Get\u003c\/span\u003e\u003cbr\u003e Business Model Canvas\u003c\/h2\u003e\n\u003cp\u003eThe document you're previewing is the authentic Nipro Business Model Canvas — not a mockup or sample — and reflects the exact content and layout you'll receive after purchase.\u003c\/p\u003e\n\u003cp\u003eUpon completing your order, you'll get this same professional, ready-to-edit file in the delivered formats, with all sections and details included as shown here.\u003c\/p\u003e\n\u003cp\u003eWe provide full transparency: what you see in the preview is the full deliverable, instantly downloadable and ready for presentation or customization.\u003c\/p\u003e\n\u003c\/div\u003e\n\u003cdiv class=\"image-section image-1_new_design\"\u003e\n\u003cimg src=\"\/cdn\/shop\/files\/GENERAL-Explore-Preview.svg\" alt=\"Explore a Preview\"\u003e\n\u003c\/div\u003e\n\u003c\/div\u003e","brand":"MatrixBCG","offers":[{"title":"Default Title","offer_id":56748995477881,"sku":"nipro-business-model-canvas","price":10.0,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0911\/3554\/1625\/files\/nipro-business-model-canvas.png?v=1772212250","url":"https:\/\/growthsharematrix.com\/products\/nipro-business-model-canvas","provider":"Growth Share Matrix","version":"1.0","type":"link"}